ĐÁNH GIÁ KẾT QUẢ HÓA XẠ TRỊ ĐỒNG THỜI UNG THƯ HỐC MIỆNG TẠI BỆNH VIỆN UNG BƯỚU THÀNH PHỐ CẦN THƠ NĂM 2024 - 2025

Abstract

Background: Oral cancer is common in head and neck cancer. Concurrent chemoradiotherapy is the primary treatment approach for locally advanced or inoperable disease. Objectives: To evaluate treatment response and identifying factors associated with response in oral cancer patients treated with concurrent chemoradiotherapy. Materials and methods: This is a descriptive cross sectional study in 27 patients with oral  squamous cell carcinoma, who was treated from January 2024 to March 2025 at Can Tho Oncology Hospital. Results: The median age at diagnosis was 53.9. The male to female rate was 8.5:1. The most common tumor subsite was the tongue (48.1%), followed by the floor of mouth (44.4%). Most of patient has stage IV disease (96.3%). 100% of patients occurred radiotherapy toxicity, with 66.7% suffering from severe (grade III-IV) oral mucositis. Most of chemotherapy toxicity is anemia. Three months after radiotherapy, complete response was observed in 18.5% of patients, and partial response in 66.7%. Pack-Years of Cigarette Smoking and KPS Smoking history and KPS status are significant prognostic factors for response to concurrent chemoradiotherapy. Conclusion: Concurrent chemoradiotherapy proved effective in over three-quarters of oral cancer patients, with acceptable toxicity.